Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Angiogenesis
Main Authors: Faughnan, Marie E., Gossage, James R., Chakinala, Murali M., Oh, S. Paul, Kasthuri, Raj, Hughes, Christopher C. W., McWilliams, Justin P., Parambil, Joseph G., Vozoris, Nicholas, Donaldson, Jill, Paul, Gitanjali, Berry, Pamela, Sprecher, Dennis L.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Netherlands 2018
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510884/
https://ncbi.nlm.nih.gov/pubmed/30191360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-018-9646-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados